KBC Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

KBC Group’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-565	Closed	-$28K	–	1889
2024 Q1	$28K	Buy	+565	New	+$30.6K	﹤0.01%	1786

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

KBC Group's MLTX Position: Q2 2024 in Review

KBC Group sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2024, closing a stake of 565 shares — an estimated $28K sold.

KBC Group first reported a position in MLTX in Q1 2024 and held it in 1 quarter. The position peaked at $28K in Q1 2024. 111 funds tracked by Wall St. Rank hold MLTX as of Q2 2024.

KBC Group reported no remaining MoonLake Immunotherapeutics position as of Q2 2024 after selling out during the quarter.
KBC Group sold 565 MoonLake Immunotherapeutics shares in Q2 2024, an estimated $28K.
KBC Group first reported a position in MoonLake Immunotherapeutics in Q1 2024 and held it in 1 quarter.
KBC Group's MoonLake Immunotherapeutics position peaked at $28K in Q1 2024.
111 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2024.

Based on KBC Group's 13F filing for Q2 2024, filed 17 Jul 2024.